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Small Molecule Inhibitors of Mucin-Type O-Linked
Glycosylation from a Uridine-Based Library
ine or threonine side chains (Figure 1) [2]. The bio-
synthesis of O-linked glycans is initiated by the family
of polypeptide N-acetyl--galactosaminyltransferases
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and Carolyn R. Bertozzi1,2,3,* (ppGalNAcTs), which transfer GalNAc from uridine di-
phosphate N-acetyl--galactosamine (UDP-GalNAc)1Department of Chemistry
2 Department of Molecular and Cell Biology onto proteins trafficking through the Golgi compartment
(Figure 1) [3]. Elaboration of the core glycopeptide,3 Howard Hughes Medical Institute
Center for New Directions in Organic Synthesis termed the Tn-antigen, by downstream glycosyltransfer-
ases affords more complex glycan structures [4]. TheseUniversity of California, Berkeley
Berkeley, California 94720 O-linked glycans are thought to play critical roles in
lubrication and protection of tissues [5–8], leukocyte4 Section of Biological Chemistry
NIDDK homing [9], the immune response [10], and the metasta-
sis of tumor cells [11].National Institutes of Health
Bethesda, Maryland 20892 While much is known about the functions of N-linked
glycans [12, 13], progress toward understanding
O-linked glycosylation has been hindered by the large
number of ppGalNAcT isoforms present in vertebrate
Summary genomes (24 in human) [3]. To date, 21 putative ppGal-
NAcTs have been cloned from various organisms [14–
The polypeptide N-acetyl--galactosaminyltransfer- 33], all of which have been biochemically characterized
ases (ppGalNAcTs, also abbreviated ppGaNTases) ini- with the exception of ppGalNAcT-8 [24]. Transcript anal-
tiate mucin-type O-linked glycosylation and therefore ysis has revealed differential tissue distribution and tem-
play pivotal roles in cell-cell communication and pro- poral regulation of ppGalNAcT expression during devel-
tection of tissues. In order to develop new tools for opment and pregnancy [34, 35]. Targeted gene deletion
studying mucin-type O-linked glycosylation, we screened of ppGalNAcT-1, -4, -5, or -13 in mice demonstrate no
a 1338 member uridine-based library to identify small apparent phenotypes with respect to development, fer-
molecule inhibitors of ppGalNAcTs. Using a high- tility, and immune function, suggesting functional redun-
throughput enzyme-linked lectin assay (ELLA), two in- dancy or compensatory regulation amongst the ppGal-
hibitors of murine ppGalNAcT-1 (KI8 M) were iden- NAcT family members [3]. However, recent studies of
tified that also inhibit several other members of the D. melanogaster mutants have shown that one ppGal-
family. The compounds did not inhibit other mamma- NAcT, pgant35A, is essential for development [27, 28].
lian glycosyltransferases or nucleotide sugar utilizing Studies of O-linked glycoprotein biosynthesis are fur-
enzymes, suggesting selectivity for the ppGalNAcTs. ther complicated by the overlapping peptide substrate
Treatment of cells with the compounds abrogated mu- specificities exhibited by the ppGalNAcT family in vitro
cin-type O-linked glycosylation but not N-linked glyco- and in vivo [3, 36, 37]. The identification of ppGalNAcTs
sylation and also induced apoptosis. These uridine that specifically recognize -GalNAc-modified glyco-
analogs represent the first generation of chemical peptides has enabled further subclassification of the
tools to study the functions of mucin-type O-linked family into peptide and glycopeptide transferases [22,
glycosylation. 23, 26]. In contrast to N-linked glycosylation, where a
single oligosaccharyl transferase catalyzes the modifi-
cation of asparagine residues within the consensus se-
Introduction quence Asn-Xaa-Ser/Thr [38], no consensus sequence
for O-linked glycosylation has been identified. Computa-
Protein glycosylation is important for a variety of cellular tional algorithms developed to predict the likelihood of
events such as protein trafficking and cell-cell interac- O-linked glycosylation from primary amino acid se-
tions [1]. There are two major forms of protein glycosy- quences have been useful for identifying mucin domains
lation, N-linked and O-linked, distinguished by their within a protein [39]. However, these semiempirical
glycosidic linkages to amino acid side chains. Mucin- methods have limited accuracy for predicting glycosyla-
type O-linked glycosylation (hereafter, all references to tion of specific residues and therefore still require exper-
O-linked glycosylation refer to the mucin-type) is the imental confirmation. Finally, structural studies of ac-
dominant form of O-linked glycosylation in higher eurk- ceptor peptide substrates suggest that ppGalNAcTs
aryotes, characterized by an N-acetyl--galactosamine may recognize -turn-like motifs rather than primary
(GalNAc) residue attached to the hydroxyl group of ser- amino acid sequence alone [40].
The discovery and design of inhibitors that target
N-linked glycan biosynthesis and processing have
*Correspondence: crb@berkeley.edu greatly increased our appreciation of N-linked glycosyl-5These authors contributed equally to this work.
ation [41–43]. In contrast, few chemical tools are avail-6Present address: Department of Medicine, Division of Infectious
able to address mucin-type O-linked glycosylation.Diseases and Geographic Medicine, Stanford University Medical
Center, Stanford, California 94305. Competitive substrate-based primers can be used to
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Figure 1. Initiation of Mucin-Type O-Linked Glycosylation by ppGalNAcTs and Elaboration into Complex O-Linked Glycans by Downstream
Glycosyltransferases
inhibit the downstream elaboration of O-linked glycans The immobilized glycopeptide product could be de-
in cells, affording truncated structures [44–48]. But these tected using the -GalNAc-specific lectin Helix pomatia
compounds do not affect the attachment of GalNAc to agglutinin (HPA) [52] conjugated to horseradish peroxi-
Ser or Thr. Inhibitors of the ppGalNAcTs that initiate dase (HRP) after addition of a chromogenic HRP sub-
O-linked glycosylation have not been reported and strate.
would be powerful tools to further our understanding of In order to correlate the change in absorbance pro-
this fundamental posttranslational modification. duced by HRP activity to the enzymatic activity of
Here we report the discovery of ppGalNAcT inhibitors mppGalNAcT-1, a standard curve for the ELLA response
from a uridine-based library designed to target enzymes was generated. Peptide 4 and glycopeptide 5, biotinyl-
that utilize UDP-sugar substrates [49]. The library con- ated at the C terminus, were constructed by Fmoc-
served the uridine moiety of the nucleotide sugar sub- based solid-phase peptide synthesis using previously
strate, while replacing the sugar and diphosphate described methods (Figure 3B) [53]. Peptide 4 and gly-
groups with drug-like diversity elements (Figure 2A). copeptide 5 were combined at various percentages,
Three different linkers were utilized to couple the uridine captured on NeutrAvidin-coated 96-well microtiter
component with a diverse array of 446 aldehydes via an plates, and detected using the HPA-HRP conjugate. The
oxime or hydrazone linkage (Figure 2B). This library has standard curve derived from this experiment correlates
previously produced selective inhibitors of the human the percentage of NeutrAvidin sites occupied by the
UDP-GlcNAc/GalNAc C4-epimerase [49] and the myco- glycopeptide with the observed signal. The absolute
bacterial UDP-galactopyranose-mutase [50]. Two com- quantity of immobilized glycopeptide can be determined
pounds were identified from the library that inhibited all based on the known binding capacity of the NeutrAvidin-
the ppGalNAcTs tested. coated plates (60 pmol/well). The standard curve
showed a dose-dependent increase in signal over a
range of 0%–15% 5 (Figure 3C). The signal reached aResults and Discussion
plateau at higher concentrations of 5, which we attrib-
uted to saturation of lectin binding. The signal to noiseDevelopment and Validation of a High-Throughput
ratio observed at 15% 5 (9 pmol) was 30-fold aboveAssay for ppGalNAcTs
background. Thus, the assay can readily detect low pi-In order to screen the library in high-throughput format,
comole amounts of the product from the ppGalNAcTwe developed a nonradioactive enzyme-linked lectin
reaction.assay (ELLA) for ppGalNAcTs. A schematic diagram of
To validate the ELLA, we measured the kinetic param-the assay is shown in Figure 3A. As an acceptor sub-
eters of mppGalNAcT-1 with UDP-GalNAc, EA2 peptidestrate, we chose the EA2 peptide (PTTDSTTPAPTTK), a
4, and UDP (details are provided in the Supplementalfragment of rat submandibular mucin [51]. This peptide
Data at http://www.chembiol.com/cgi/content/full/11/has been previously shown to be an efficient substrate
3/337/DC1). The KM values of UDP-GalNAc and EA2 pep-for murine (m) ppGalNAcT-1 and is preferentially glyco-
tide 4 were determined to be 13.9  1.8 M and 48.0 sylated at the fourth Thr residue from the N terminus
4.0 M, respectively. The KI value for the product UDP(underlined) [26]. Biotinylation of EA2 allowed capture of
(glyco)peptides onto 96-well NeutrAvidin-coated plates. was 251.1  78.0 M. These values are similar to those
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Figure 2. Uridine-Based Library
(A) Design of uridine-based library as nucleotide sugar mimics.
(B) Retrosynthesis of the uridine-based library. Compounds are numbered according to the uridine linker (1, 2, and 3) followed by the aldehyde
(i.e., 1-299 or 1A-148A; a complete list of aldehydes used in the library synthesis is provided in the Supplemental Data at http://www.chembiol.
com/cgi/content/full/11/3/337/DC1).
previously determined using a radiolabel capture assay M and 7.8  1.0 M versus UDP-GalNAc, respectively
(Figure 4B). Both compounds were competitive with re-[20, 54].
spect to UDP-GalNAc and bind approximately 2-fold
greater than UDP-GalNAc (KM  14 M) and 30-foldPreliminary Screening of the Uridine-Based
greater than UDP (KI  250 M). The compounds ap-Library with mppGalNAcT-1
peared to be noncompetitive with respect to EA2 pep-Using the ELLA, we performed preliminary screens of
tide 4 (Supplemental Data at http://www.chembiol.com/the 1338 member uridine-based library [49] at 40 M
cgi/content/full/11/3/337/DC1), a finding consistent withwith mppGalNAcT-1. From the preliminary screens, 32
a random sequential mechanism reported by Wragg etinitial hits displayed over 70% inhibition (Supplemental
al. [54].Data at http://www.chembiol.com/cgi/content/full/11/
To determine the contributions of the uridine and alde-3/337/DC1). After rescreening these initial hits at 8 M
hyde components to binding, we assayed aldehyde 68Aand resynthesis of confirmed hits, two mppGalNAcT-1
and the parent aminooxy uridine analogs 1 and 2 forinhibitors 1-68A and 2-68A were identified (Figure 4A).
inhibitory activity. While uridine analogs 1 and 2 showedThe compounds comprised the same aldehyde compo-
no inhibition at concentrations up to 400 M (Supple-nent (68A) linked via an oxime to two different uridine
mental Data at http://www.chembiol.com/cgi/content/scaffolds, 1 and 2. Interestingly, the aldehyde compo-
full/11/3/337/DC1), compound 68A exhibited competi-nent has a trihydroxybenzene functionality that resem-
tive inhibitory activity with a KI value of 34.3  5.5 Mbles a monosaccharide.
(Figure 4B). These data suggest that the binding affinity
of 68A was increased approximately 5-fold when cou-Kinetic Analysis of Uridine-Based Inhibitors
pled to uridine analogs 1 or 2. It is interesting to notewith mppGalNAcT-1
that the KI values for compounds 1-68A and 2-68A areTo determine the modes of 1-68A and 2-68A inhibition,
similar despite the different linker lengths, suggestingwe evaluated their inhibitory activity versus both sub-
that the aldehyde component contributes significantlystrates UDP-GalNAc and EA2 peptide 4. The KI values
for 1-68A and 2-68A were determined to be 7.8  0.1 to binding. However, the adduct of aldehyde 68A with
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Figure 3. Enzyme-Linked Lectin Assay for Detecting ppGalNAcT Activity
(A) Schematic of the enzyme-linked lectin assay (ELLA).
(B) Biotinylated EA2 (glyco)peptides 4 and 5. Sites of glycosylation bearing -GalNAc are underlined. These were chosen based on an initial report
that mppGalNAcT-1 modifies Thr2 with GalNAc [18]. It was later established that mppGalNAcT-1 modifies EA2 at Thr7 rather than Thr2 [26].
(C) ELLA standard curve generated with EA2 (glyco)peptides 4 and 5. Each point on the graph represents the average of duplicates; error
bars represent the high and low values.
uridine analog 3 (Figure 2), the longest of the three uri- NAcTs 1–5, 7, 10, and 11 (Table 1, entries 1–8). Their
inhibitory activities were similar with all ppGalNAcT iso-dine linkers, showed no inhibitory activity in preliminary
screens, suggesting the structure and/or length of the forms tested, which suggests that 1-68A and 2-68A are
broad-spectrum inhibitors of the ppGalNAcT family. Tolinker is a critical determinant of binding.
determine the inhibitory activities of the compounds
among the broader family of glycosyltransferases,Inhibitory Activity against Other Related Enzymes
To evaluate the activities of compounds 1-68A and 1-68A and 2-68A were tested against bovine 1-4galac-
tosyltransferase (1-4GalT) [55] and porcine 1-3galac-2-68A with other ppGalNAcT isoforms, IC50 measure-
ments for both compounds were performed with ppGal- tosyltransferase (1-3GalT) [56], using a previously re-
Figure 4. ppGalNAcT Inhibitors Identified from the Uridine-Based Library
(A) Structures of mppGalNAcT-1 inhibitors 1-68A and 2-68A and parent aldehyde 68A.
(B) KI measurements for 1-68A, 2-68A, and 68A with respect to UDP-GalNAc, against mppGalNAcT-1. The concentration of EA2 peptide 4
was held constant at 50 M while the concentration of UDP-GalNAc was varied from 25 to 400 M. Inhibitor concentrations were varied from
6 to 48 M. The various concentrations of inhibitor are represented by the following symbols: closed diamond  0 M, closed square  6
M, closed up triangle  12 M, closed circle  24 M, and open circle  48 M. Each point on the graph represents the average of
duplicates; error bars represent the high and low values.
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on O-linked glycosylation in cells. To directly monitorTable 1. IC50 Values for 1-68A and 2-68A with ppGalNAcTs 1–5,
7, 10, 11, 1-4GalT, and 1-3GalT ppGalNAcT activities in cells, we chose Jurkat cells (hu-
man T cell lymphoma) that are known to produce the2.1-68A (M) 2.2-68A (M)
Tn-antigen (Figure 1) as their O-linked glycans [58].
mppGalNAcT-1 21  1 24  2 Changes in Tn-antigen expression on the surface of
mppGalNAcT-2 15  1 18  2
Jurkat cells were monitored by HPA binding followedmppGalNAcT-3 40  2 38  4
by flow cytometry analysis. Con A staining of N-linkedmppGalNAcT-4 30  5 20  5
glycans was used as a control for nonspecific inhibitionrppGalNAcT-5 20  2 26  9
rppGalNAcT-7 22  2 27  2 of protein glycosylation [59]. As shown in Figure 5A,
rppGalNAcT-10 7  1 6  1 both 1-68A and 2-68A inhibited HPA staining of Jurkat
mppGalNAcT-11 39  3 32  3 cells in a dose-dependent manner (EC50 80 M) with
1-4GalT 500 500 no significant effect on Con A staining. However, forward
1-3GalT 500 500
and side scatter analysis of the cells treated with either
The requirement of glycopeptides as substrates for ppGalNAcT-7 compound for 2 days indicated that a morphological
and -10 precluded the use of the ELLA, as both the substrate and change characteristic of apoptosis had occurred. In-
product bind HPA-HRP. Thus, the radiolabel capture assay was
deed, Annexin-V [60] staining of Jurkat cells treated withemployed to measure the IC50 values of 1-68A and 2-68A with ppGal-
1-68A or 2-68A confirmed the induction of apoptosisNAcT-7 and -10 using MUC5AC** (GTTPSPVPTTSTTSAP) glycopep-
(Figure 5B) at inhibitor concentrations that also abrogatetide, previously shown to be substrate for both enzymes [22, 26].
IC50 values of 1-68A and 2-68A with ppGalNAcT-5 were performed HPA staining.
with -FLAG purified enzyme and radiolabel capture assay, due to It is possible that compounds 1-68A and 2-68A induce
low activity and stability of the crude enzyme. m, murine; r, rattus. apoptosis independently of their effects on O-linked gly-
cosylation and that changes in membrane architecture
associated with the process affect lectin staining ofported continuous colorimetric assay [57]. Neither
cells. We therefore sought to address the effects ofcompound was active against 1-4GalT or 1-3GalT
compounds known to induce apoptosis by glycosyla-at the highest concentration tested (500 M) (Table 1,
tion-independent mechanisms on lectin staining. Jurkatentries 9 and 10). While every UDP-sugar utilizing en-
cells were treated with the pro-apoptotic drugs doxoru-zyme in the vertebrate genome has not been evaluated,
bicin [61] and campothecin [62], which inhibit topoisom-the lack of inhibitory activity of 1-68A and 2-68A against
erases I and II, respectively, and evaluated for HPA, Con1-4GalT and 1-3GalT demonstrates that these com-
A, and Annexin V staining. As shown in Figures 5C andpounds are not general inhibitors of inverting or retaining
5D, doxorubicin and campothecin induced Annexin Vglycosyltransferases. It should also be noted that 1-68A
binding at levels comparable to 1-68A. In contrast toand 2-68A were not identified in screens of the uridine-
1-68A, doxorubicin and campothecin reduced both HPAbased library against the UDP-GlcNAc/GalNAc
and Con A staining of Jurkat cells. Thus, the physiologi-C4-epimerase [49] or UDP-galactopyranose mutase [50].
cal changes associated with apoptosis alone cannotCollectively, these observations suggest that 1-68A and
account for the selective reduction in HPA staining ob-2-68A are selective inhibitors of the ppGalNAcT family
served with 1-68A. Moreover, it is unlikely that the ef-and do not function as nonspecific inhibitors of UDP-
fects of 1-68A simply reflect a global disruption in me-sugar utilizing enzymes.
tabolism, as one would expect a similar effect on
N-linked glycan expression.Evaluation of 1-68A and 2-68A Inhibitory
To determine if the inhibition of O-linked glycosylationActivity in Cells
and induction of apoptosis by 1-68A and 2-68A wereHaving demonstrated that 1-68A and 2-68A inhibit the
ppGalNAcTs in vitro, we sought to evaluate their effects specific to Jurkat cells, we evaluated the effects of 1-68A
Figure 5. Effects of ppGalNAcT Inhibitors
and the Apoptosis Inducers Doxorubicin and
Campothecin in Jurkat Cells
(A) Lectin staining of N-linked (Con A, dashed
lines) and O-linked (HPA, solid lines) glycans
on Jurkat cells treated with 1-68A (closed
square) or 2-68A (closed diamond).
(B) Evaluation of apoptosis by fluorescein iso-
thiocyanate (FITC)-labeled Annexin-V stain-
ing of Jurkat cells treated with 1-68A (closed
square) or 2-68A (closed diamond).
(C) Lectin staining of N-linked (Con A) and
O-linked (HPA) glycans on Jurkat cells treated
with doxorubicin (10 M) or campothecin
(10 M).
(D) Evaluation of apoptosis by FITC-labeled
Annexin-V staining of Jurkat cells treated with
doxorubicin (10 M) or campothecin (10 M).
MFI, mean fluorescence intensity of the total
cell population. Each point on the graph rep-
resents the average of duplicates; bars repre-
sent the high and low values.
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Figure 6. Fluorescence Microscopy Analysis of HEK 293T Cells for O-Linked Glycosylation and Apoptosis
(A) Cells treated with 100 M 1-68A.
(B) Cells treated with DMSO alone. Green, FITC-jacalin staining; blue, nuclei counterstain with Hoechst 33342; red, TUNEL staining. Scale bar
applies to both images.
on human embryonic kidney (HEK) 293T cells. In this the compounds may induce apoptosis through a gly-
cosylation-independent mechanism, resulting in abro-case, O-linked glycans on the cell surface were moni-
tored by staining with jacalin, a lectin that binds core 1 gation of numerous metabolic pathways. However, the
compounds did not affect N-linked glycosylation, sug-structures (Gal1,3-GalNAc1-Ser/Thr) [63]. To evaluate
apoptosis in HEK cells, TUNEL staining for DNA frag- gesting a more specific mechanism. The compounds
reported here are the first inhibitors of the ppGalNAcTmentation was performed [64]. As shown in Figure 6A,
1-68A inhibits jacalin staining at 100 M and increases family and provide a promising starting point for the
development of more potent and selective inhibitorsTUNEL staining compared to untreated HEK cells (Fig-
ure 6B). Thus, 1-68A appears to block O-linked glycosyl- for individual ppGalNAcTs.
ation and induce apoptosis in HEK cells as well as in
Experimental ProceduresJurkat cells.
Methyl 2-acetamido-2-deoxy--D-glucopyranoside (OMeGlcNAc),
pyruvate kinase, lactate dehydrogenase, phosphoenolpyruvate,Significance
NADH, and UDP-GalNAc were purchased from Sigma. HPA-HRP,
FITC-HPA, FITC-Con A, and FITC-jacalin were from E-Y Labora-Chemical tools for studying O-linked glycosylation
tories. Transparent 96-well Reacti-Bind NeutrAvidin-coated plates
would facilitate functional studies of this critical post- and the HRP substrate 3,3,5,5-tetramethyl benzidine (TMB) were
translational modification. Toward this end, we sought purchased from Pierce. Doxorubicin hydrochloride, campothecin,
inhibitors of the ppGalNAcTs that initiate O-linked gly- UDP-Gal, N-acetylactosamine (LacNAc), bovine 1-4GalT, and por-
cine 1-3GalT were purchased from Calbiochem. Aldehydes werecosylation. Two compounds were identified from a
purchased from Aldrich, ChemDiv, or ChemBlock as listed in theuridine-based library using a novel high-throughput
Supplemental Data at http://www.chembiol.com/cgi/content/full/ELLA. They were competitive with respect to UDP-
11/3/337/DC1.
GalNAc with KI values of approximately 8 M and did Enzyme assays were quantified using a Molecular Devices UV/
not inhibit other enzymes such as 1-4GalT or 1- Vis 96-well plate reader (SpectraMax 190). RP-HPLC was performed
3GalT. The discovery of these inhibitors further vali- using a Rainin Dynamax SD-200 HPLC system with 230 nm detection
on a Microsorb C-18 analytical column (4.6  250 mm) at a flowdates the uridine-based library as a source of lead
rate of 1 ml/min or a preparative column (25  250 mm) at a flowcompounds for UDP-sugar utilizing enzymes. The
rate of 20 ml/min.2,3,4-trihydroxybenzene motif present in both com-
All 1H and 13C NMR spectra were recorded on a Bruker DRX 500
pounds is reminiscent of a monosaccharide and con- MHz NMR spectrometer. Chemical shifts are reported in ppm rela-
tributes significantly to binding. It is notable that the tive to tetramethylsilane. Coupling constants (J ) are reported in Hz.
compounds bind with higher affinity than UDP-GalNAc Fast atom bombardment (FAB) and electrospray (ES) mass spectra
were obtained at the UC Berkeley Mass Spectrometry Laboratory.without charged moieties that mimic the pyrophos-
Jurkat cells were grown in RPMI-1640 media supplemented withphate group, which has been a major challenge in
10% FCS, 100 units/ml penicillin, and 0.1 mg/ml streptomycin. HEKglycosyltransferase inhibitor design [65].
293T cells were grown in MEM supplemented with 10% FCS, 2 mM
The compounds disrupted O-linked glycosylation in L-glutamine, and Earle’s BSS adjusted to contain 1.5 g/l sodium
cells while also inducing apoptosis. Experiments are bicarbonate, 0.1 mM nonessential amino acids, and 1.0 mM sodium
currently underway to dissect the relationship of these pyruvate. Cells were incubated in a 5% CO2 humidified incubator
at 37	C.effects. It is worth noting that the compounds exhibit
cellular effects despite their polar nature. This sug-
Solid-Phase Peptide Synthesisgests they have a mechanism to enter cells, either by
The biotinylated peptides and glycopeptides were generated bydiffusion through membranes or by active uptake. It
standard Fmoc-based solid-phase peptide synthesis methods using
is possible that O-linked glycan disruption promotes N-Fmoc-Thr(Ac3--D-GalNAc)-OH [53] as a glycosylated amino
apoptosis, similar to the toxic effects of the N-linked acid building block. Peptides were purified by RP-HPLC eluting with
10%–40% MeCN/H2O with 0.1% TFA. C-terminal biotinylated EA2glycosylation inhibitor tunicamycin [41]. Alternatively,
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(4): LRMS (ES): calculated for C71H119N19O25S (M
H
) 1670.9, found 73.2, 69.8. HRMS (FAB): calculated for C16H17N3O9 (M
H
) 396.1039,
found 396.1043.1670.7. C-terminal biotinylated EA2* (5): LRMS (ES): calculated for
C79H132N20O30S (M
H
) 1874.1, found 1874.1. MUC5AC** LRMS (ES): 2-68A 1H NMR (500 MHz, CD3OD):  8.33 (s, 1), 7.60 (d, 1, J 
8.1), 6.73 (d, 1, J  8.6), 6.41 (d, 1, J  8.5), 5.70 (d, 1, J  4.8), 5.60calculated for C79H132N19O35 (M
H
) 1907.0, found 954.5 (M
2H
).
(d, 1, J  8.0), 4.63 (app s, 1), 4.21 (app t, 1, J  5.0), 4.04–4.02 (m,
2), 3.65–3.54 (m, 2). 13C NMR (125 MHz, MeOD):  171.1, 164.6, 153.0,Expression of ppGalNAcTs
150.8, 148.6, 146.0, 141.8, 132.5, 121.2, 108.9, 107.5, 101.4, 91.0,COS-7 cells were transiently transfected with plasmids encoding
82.2, 73.2, 72.4, 70.8, 40.4. HRMS (FAB): calculated for C18H20N4O10truncated secreted ppGalNAcTs 1–5, 7, 10, and 11 as previously
(M
H
) 453.1253, found 453.1258.described [19]. The crude conditioned medium was used as the
enzyme source.
Evaluation of 1-68A, 2-68A, Doxorubicin,
and Campothecin in Jurkat CellsELLA for ppGalNAcTs
Jurkat cells were seeded at 250,000 cells/well (determined byStandard reaction conditions for ppGalNAcT assays were as follows.
Coulter cell counter) in 12-well polystyrene tissue culture plates inThe reaction mixture contained the following components in a final
1.0 ml of media and treated with various concentrations of 1-68Avolume of 25 l: 10 mM MnCl2, 40 mM sodium cacodylate, 40 mM or 2-68A from 50 mM DMSO stock solutions or doxorubicin or cam-
-mercaptoethanol, 0.1% Triton X-100 [pH 6.5], 5 l of conditioned
pothecin from 1 mM DMSO stock solutions. After 2 days, cells weremedia, and various concentrations of EA2 peptide 4, UDP-GalNAc,
harvested, washed twice with PBS buffer (PBS [pH 7.4], 0.1% FCS,and inhibitor. All uridine-based compounds were dissolved in
0.1% NaN3 w/v), and stained with FITC-HPA (1 g/ml) or FITC-ConDMSO. We limited the concentration of DMSO in the reaction mix-
A (5 g/ml with 1 mM CaCl2) in PBS (pH 7.4) in the dark for 1 hr atture to 2% (v/v), as higher concentrations decreased ppGalNAcT
4	C. Cells were washed twice with PBS buffer, resuspended in 300activity. For inhibitor assays, reaction mixtures for positive controls
l of PBS buffer, and analyzed by flow cytometry (FacsCaliber, BDalso contained 2% DMSO. Unless otherwise stated, inhibitor assays
Instruments). Annexin-V staining was performed according to thewere performed using 20 M UDP-GalNAc and 50 M EA2 peptide
manufacturer’s protocols (Invitrogen).4, the KM values for both substrates. Reactions were incubated at
37	C and were terminated by the addition of 10 l of 0.1 M EDTA.
Evaluation of 1-68A and 2-68A in HEK 293T CellsAll experiments were performed in duplicate. Reaction rates were
HEK 293T cells were seeded at 20,000 cells/ml in a 24-well platelinear over the period monitored (20–30 min).
(Costar) fit with glass coverslips (Fisher). After 24 hr of incubation96-well NeutrAvidin-coated plates were prewashed 3 times with
with 100 M 1-68A, cells were washed twice with PBS (pH 7.4) and200 l of wash buffer (25 mM Tris, 150 mM NaCl, 0.1% bovine serum
fixed with 4% paraformaldehyde-PBS for 1 hr at rt. The cells werealbumin (BSA) (w/v), and 0.05% Tween (v/v) [pH 7.2]). Reactions
washed twice with PBS and incubated with permeabilization solu-were then transferred to the 96-well plates, incubated for 1 hr at rt,
tion (0.1% Triton X-100 in 0.1% sodium citrate, freshly prepared)and subsequently washed 3 times with 200l of phosphate-buffered
for 2 min on ice. After the cells were washed twice with PBS, 50 lsaline (PBS) containing 0.5% BSA and 0.05% Tween (pH 7.1). A 100
of TUNEL reaction mixture (1:10 dilution, Boehringer Mannheim) wasl solution of HPA-HRP in standard PBS buffer (1 g/ml, pH 7.4)
added. The plate was covered with parafilm to avoid evaporativewas added and the reaction was incubated for 1 hr at rt. After 3
loss and incubated in a humidified atmosphere for 1 hr at 37	C inwashes with 200 l of PBS, bound HPA-HRP was quantified by the
the dark. The cells were then rinsed three times with PBS andaddition of 100 l of TMB peroxide solution. The solutions were
blocked with 2% BSA in PBST (PBS, 0.05% Tween 20) for 30 minincubated for 5–15 min in the dark at rt. HRP activity was terminated
at rt. Following one wash with PBS, the cells were incubated withby the addition of 50 l of 2 N H2SO4, and the resulting solution was
100 l of FITC-jacalin (4 g/ml in PBST) for 1 hr at 37	C in the dark.analyzed at 450 nm using a UV/Vis microtiter plate reader. The
The cells were washed three times with PBS, counterstained withamount of product generated by the ppGalNAcT was extrapolated
Hoechst 33342 (Molecular Probes), and mounted with Fluoro-from absorbance values using an equation fit to the standard curve
mount-G aqueous medium (Electron Microscopy Sciences). Slidesderived from Origin 6.1 software.
were analyzed by fluorescence microscopy (Zeiss, using Openlab
software).
Radiolabel Capture Assay for rppGalNAcT-5, -7, and -10
Radiolabel capture assays using 14C-labeled UDP-GalNAc were per-
Supplemental Data
formed as previously described with various concentrations of
Supplemental Data include the complete list of compounds com-
1-68A or 2-68A in 2% DMSO [26].
prising the uridine library, detailed synthetic procedures, and experi-
mental details for Ki and IC50 measurements. These materials can
Continuous Assay for 1-4GalT and 1-3GalT Activity be found online at http://www.chembiol.com/cgi/content/full/11/3/
The enzymatic reactions contained the following components in a 337/DC1.
final volume of 100 l: 20 mM MnCl2, 100 mM sodium cacodylate
(pH 6.5), 5 U of pyruvate kinase, 5 U of lactate dehydrogenase, 2 mM Acknowledgments
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